# OnCo record imatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/imatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "imatinib" ;
  schema:name "Imatinib"@en ;
  schema:alternateName "STI571"@en, "STI-571"@en, "Glivec"@en, "Gleevec" ;
  schema:description "The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy."@en ;
  schema:url <https://onco.cc/drugs/imatinib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Imatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q177094> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Imatinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)" ;
  onco:approval "US 2001: Chronic myeloid leukaemia", "US 2002: KIT+ GIST" ;
  onco:acceleratedApproval "US 2001-05-10: CML in blast crisis, accelerated phase, or in chronic phase after failure of of interferon-alpha", "US 2002-02-01: KIT (CD117) positive unresectable and/or metastatic GIST", "US 2002-12-20: Newly diagnosed adults with Philadelphia chromosome positive CML", "US 2003-05-20: Pediatric patients with recurrent PH+ chronic phase CML after stem cell transplant or who are resistant to interferon alpha therapy", "US 2006-09-27: Newly diagnosed Philadelphia positive CML in pediatric patients", "US 2008-12-19: Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)" ;
  onco:acceleratedApprovalConfirmed "US 2003-12-08: CML in blast crisis, accelerated phase, or in chronic phase after failure of of interferon-alpha", "US 2006-09-27: Pediatric patients with recurrent PH+ chronic phase CML after stem cell transplant or who are resistant to interferon alpha therapy", "US 2008-09-26: KIT (CD117) positive unresectable and/or metastatic GIST", "US 2009-05-27: Newly diagnosed adults with Philadelphia chromosome positive CML", "US 2011-04-01: Newly diagnosed Philadelphia positive CML in pediatric patients", "US 2012-01-31: Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)" ;
  onco:related <https://onco.cc/technologies/american-ginseng-fatigue/>, <https://onco.cc/technologies/st-johns-wort-interaction/>, <https://onco.cc/biomarkers/kit-d816v/>, <https://onco.cc/biomarkers/bcr-abl1-transcript/> ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cml-chronic-phase/>, <https://onco.cc/cancers/gist-kit-exon-11/>, <https://onco.cc/cancers/all-paediatric-ph-positive/>, <https://onco.cc/cancers/dermatofibrosarcoma-protuberans/>, <https://onco.cc/cancers/mucosal-melanoma/>, <https://onco.cc/cancers/acral-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kit/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/natco/> ;
  onco:pathways <https://onco.cc/pathways/bcr-abl1-signalling/> ;
  onco:trials <https://onco.cc/trials/nct07406633/>, <https://onco.cc/trials/nct04971226/>, <https://onco.cc/trials/nct03459534/> .